Valeant Pharmaceuticals Intl (VRX) Given New $27.00 Price Target at TD Securities

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) had its price objective raised by stock analysts at TD Securities from $20.00 to $27.00 in a research note issued to investors on Friday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. TD Securities’ price target points to a potential upside of 13.21% from the stock’s current price.

A number of other equities analysts have also issued reports on VRX. Mizuho increased their price target on Valeant Pharmaceuticals Intl from $7.00 to $10.00 and gave the company an “underperform” rating in a research note on Friday, December 15th. Piper Jaffray Companies reiterated a “sell” rating and set a $14.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Sunday, September 17th. Canaccord Genuity reiterated a “hold” rating and set a $16.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, October 3rd. HC Wainwright reiterated a “hold” rating and set a $17.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Monday, September 18th. Finally, Vetr upgraded Valeant Pharmaceuticals Intl from a “strong sell” rating to a “sell” rating and set a $12.46 price objective for the company in a research report on Thursday, September 28th. Six analysts have rated the stock with a sell rating, ten have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $18.20.

Shares of Valeant Pharmaceuticals Intl (VRX) traded up $0.80 during mid-day trading on Friday, reaching $23.85. The company had a trading volume of 22,330,000 shares, compared to its average volume of 20,590,000. Valeant Pharmaceuticals Intl has a 1-year low of $8.31 and a 1-year high of $24.43. The company has a market cap of $8,320.00, a price-to-earnings ratio of 6.12, a price-to-earnings-growth ratio of 0.68 and a beta of -0.22. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03.

In other Valeant Pharmaceuticals Intl news, Director John Paulson purchased 344,216 shares of the stock in a transaction dated Thursday, November 16th. The shares were bought at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the transaction, the director now owns 94,559 shares in the company, valued at approximately $1,361,649.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.87% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Riggs Asset Managment Co. Inc. grew its position in Valeant Pharmaceuticals Intl by 118.2% during the third quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after buying an additional 4,512 shares in the last quarter. Cetera Investment Advisers acquired a new stake in Valeant Pharmaceuticals Intl during the second quarter worth about $192,000. Harbour Capital Advisors LLC acquired a new stake in Valeant Pharmaceuticals Intl during the third quarter worth about $224,000. American Century Companies Inc. acquired a new stake in Valeant Pharmaceuticals Intl during the third quarter worth about $238,000. Finally, Moors & Cabot Inc. grew its position in Valeant Pharmaceuticals Intl by 32.3% during the second quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock worth $267,000 after buying an additional 3,725 shares in the last quarter. 49.45% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/05/valeant-pharmaceuticals-intl-vrx-given-new-27-00-price-target-at-td-securities.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Leave a Reply